<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554020</url>
  </required_header>
  <id_info>
    <org_study_id>120216-SUS-NWC-BSS-GP</org_study_id>
    <nct_id>NCT01554020</nct_id>
  </id_info>
  <brief_title>Blood Sugar Take Care and Glucose Metabolism</brief_title>
  <official_title>Effect of Blood Sugar Take Care on Glucose Metabolism, Determinants of Metabolic Syndrome, and Quality of Life in Prediabetic Adults: A Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewChapter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NewChapter, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective international clinical trial is a two-arm, double-blind, randomized,&#xD;
      placebo-controlled, parallel-group, multicenter study. 112 prediabetic subjects will be&#xD;
      randomized to Blood Sugar Take Care or placebo. Randomization will be stratified by gender.&#xD;
      The intervention period is 12 weeks. The primary outcome is fasting glucose levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of CRO&#xD;
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis Model Assessment of Insulin Resistance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative insulin sensitivity check index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion/insulin resistance index</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-molecular weight adiponectin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids (total cholesterol, HDL, LDL, VLDL, triglycerides)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>height/weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of Life Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive metabolic panel</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Multiherb product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Herbal product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blood Sugar Take Care</intervention_name>
    <description>One 1200 mg soft gel capsule administered 3X/day for duration of study</description>
    <arm_group_label>Multiherb product</arm_group_label>
    <other_name>BSTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One 1200 mg soft-gel capsule administered 3X/day for duration of study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        SUBJECT INCLUSION CRITERIA: STEP 1&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Subject meets American Diabetes Association criteria for diabetes testing in&#xD;
             asymptomatic, undiagnosed individuals:&#xD;
&#xD;
               1. If age ≥45 years, subject must have a body mass index ≥ 25 kg/m2 for United&#xD;
                  States and ≥ 24 kg/m2 for Indonesia&#xD;
&#xD;
               2. If age &lt;45 years, subject must have a body mass index ≥ 25 kg/m2 for United&#xD;
                  States and ≥ 24 kg/m2 for Indonesia AND present with at least one of the&#xD;
                  following risk factors:&#xD;
&#xD;
                    -  Have a first-degree relative with diabetes&#xD;
&#xD;
                    -  Habitually physically inactive&#xD;
&#xD;
                    -  Race is African-American, Hispanic American, Native American, Asian&#xD;
                       American, or Pacific Islander&#xD;
&#xD;
                    -  Have delivered a baby weighing &gt;9 lb or have been diagnosed with gestational&#xD;
                       diabetes mellitus&#xD;
&#xD;
                    -  Hypertensive (≥140/90)&#xD;
&#xD;
                    -  Known HDL cholesterol level 35 mg/dl&#xD;
&#xD;
                    -  Known triglyceride level ≥250 mg/dl&#xD;
&#xD;
                    -  On previous testing, had impaired glucose tolerance or impaired fasting&#xD;
                       glucose&#xD;
&#xD;
                    -  History of vascular disease&#xD;
&#xD;
          3. Stable body weight (&lt;5% change) in the last 3 months&#xD;
&#xD;
          4. Agree to use contraception throughout study period, unless postmenopausal or&#xD;
             surgically sterile (females only)&#xD;
&#xD;
          5. Able to understand the nature and purpose of the study including potential risks and&#xD;
             side effects&#xD;
&#xD;
          6. Willing to consent to study participation and to comply with study requirements&#xD;
&#xD;
        SUBJECT EXCLUSION CRITERIA&#xD;
&#xD;
          1. Known diabetes (type I or II)&#xD;
&#xD;
          2. Recent use (within 2 weeks of screening) of any dietary supplement including vitamin&#xD;
             and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal&#xD;
             ingredient/product that significantly affects glucose or lipid metabolism&#xD;
&#xD;
          3. Recent use (within 4 weeks of screening) of any prescription or OTC medication that&#xD;
             significantly affects glucose or lipid metabolism, including but not limited to,&#xD;
             sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase&#xD;
             inhibitors, DPP-4 inhibitors, systemic corticosteroids, statins, fibrates, niacin, and&#xD;
             bile acid sequestrants&#xD;
&#xD;
          4. Daily use of nonsteroidal anti-inflammatory drugs (NSAIDS); (daily baby aspirin use&#xD;
             acceptable)&#xD;
&#xD;
          5. Any comorbidity that could, in the opinion of the investigator, preclude the subject's&#xD;
             ability to successfully and safely complete the study or that may confound study&#xD;
             outcomes&#xD;
&#xD;
          6. Anticipated changes in dietary patterns or physical activity levels during the study,&#xD;
             including attempts at body weight reduction&#xD;
&#xD;
          7. Eating disorder&#xD;
&#xD;
          8. Polycystic ovary syndrome&#xD;
&#xD;
          9. Known allergies to any substance in the study product&#xD;
&#xD;
         10. Pregnant or breastfeeding women&#xD;
&#xD;
         11. History of alcohol, drug, or medication abuse&#xD;
&#xD;
         12. Participation in another study with any investigational product within 3 months of&#xD;
             screening&#xD;
&#xD;
         13. Recent (&lt;3 months) gastrointestinal surgery or any planned surgery during the&#xD;
             treatment period&#xD;
&#xD;
        SUBJECT INCLUSION CRITERIA: STEP 2&#xD;
&#xD;
        1. Fasting glucose between 95 and 130 mg/dl, based on portable glucometer reading&#xD;
&#xD;
        SUBJECT INCLUSION CRITERIA: STEP 3&#xD;
&#xD;
          1. Impaired fasting glucose, based on the American Diabetes Association definition of&#xD;
             fasting serum glucose between 100 and 125 mg/dl&#xD;
&#xD;
          2. Impaired glucose tolerance, based on the American Diabetes Association definition of&#xD;
             serum glucose between 140 and 199 mg/dl 2 hours after a 75 g glucose load&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Miller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sprim Advanced Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SPRIM</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood glucose</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Oral glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

